SCHEMBL3383016

SCHEMBL3383016

NC(c1ccccn1)c1ncnc2scc(-c3ccc4c(c3)OCCO4)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.41
USP2 O75604 1/20 0.41
PAX8 Q06710 1/20 0.41
PIP4K2C Q8TBX8 1/20 0.41
SMN1; SMN2 Q16637 7/20 0.41
LMNA P02545 6/20 0.41
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
MAPT P10636 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
DAPK3 O43293 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
ABL1 P00519 1/20 0.37
NTRK1 P04629 1/20 0.37
LCK P06239 1/20 0.37
CSF1R P07333 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368448 0.94 HTT (0.47) HTTUSP2PAX8PIP4K2CSMN1; SMN2
SCHEMBL3384944 0.85 FGFR1 (0.37) HTTUSP2PAX8PIP4K2CSMN1; SMN2
SCHEMBL3382727 0.83 KDR (0.41) HTTPIP4K2CSMN1; SMN2LMNAKMT2A
SCHEMBL2369059 0.82 FGFR1 (0.56) HTTSMN1; SMN2LMNADAPK3PRKD3
SCHEMBL3381240 0.82 LMNA (0.48) HTTPIP4K2CSMN1; SMN2LMNAKMT2A
SCHEMBL3387950 0.80 LMNA (0.52) HTTPAX8PIP4K2CSMN1; SMN2LMNA
SCHEMBL3385743 0.80 HTT (0.54) HTTPIP4K2CSMN1; SMN2LMNAKMT2A
SCHEMBL2369179 0.80 HTT (0.38) HTTUSP2PAX8PIP4K2CSMN1; SMN2
SCHEMBL3385844 0.80 PIP4K2C (0.46) HTTPIP4K2CSMN1; SMN2LMNAKMT2A
SCHEMBL3387448 0.80 PIP4K2C (0.46) HTTPAX8PIP4K2CSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 HTT 543/4885USP2 4839/4885PAX8 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.